Cargando…

Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study

The immune response involved in each phase of type 2 diabetes (T2D) development might be different. We aimed to identify novel inflammatory markers that predict progression from normoglycemia to pre-diabetes, incident T2D and insulin therapy. We used plasma levels of 26 inflammatory markers in 971 s...

Descripción completa

Detalles Bibliográficos
Autores principales: Brahimaj, Adela, Ligthart, Symen, Ghanbari, Mohsen, Ikram, Mohammad Arfan, Hofman, Albert, Franco, Oscar H., Kavousi, Maryam, Dehghan, Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380703/
https://www.ncbi.nlm.nih.gov/pubmed/28258520
http://dx.doi.org/10.1007/s10654-017-0236-0
_version_ 1782519798225174528
author Brahimaj, Adela
Ligthart, Symen
Ghanbari, Mohsen
Ikram, Mohammad Arfan
Hofman, Albert
Franco, Oscar H.
Kavousi, Maryam
Dehghan, Abbas
author_facet Brahimaj, Adela
Ligthart, Symen
Ghanbari, Mohsen
Ikram, Mohammad Arfan
Hofman, Albert
Franco, Oscar H.
Kavousi, Maryam
Dehghan, Abbas
author_sort Brahimaj, Adela
collection PubMed
description The immune response involved in each phase of type 2 diabetes (T2D) development might be different. We aimed to identify novel inflammatory markers that predict progression from normoglycemia to pre-diabetes, incident T2D and insulin therapy. We used plasma levels of 26 inflammatory markers in 971 subjects from the Rotterdam Study. Among them 17 are novel and 9 previously studied. Cox regression models were built to perform survival analysis. Main Outcome Measures: During a follow-up of up to 14.7 years (between April 1, 1997, and Jan 1, 2012) 139 cases of pre-diabetes, 110 cases of T2D and 26 cases of insulin initiation were identified. In age and sex adjusted Cox models, IL13 (HR = 0.78), EN-RAGE (1.30), CFH (1.24), IL18 (1.22) and CRP (1.32) were associated with incident pre-diabetes. IL13 (0.62), IL17 (0.75), EN-RAGE (1.25), complement 3 (1.44), IL18 (1.35), TNFRII (1.27), IL1ra (1.24) and CRP (1.64) were associated with incident T2D. In multivariate models, IL13 (0.77), EN-RAGE (1.23) and CRP (1.26) remained associated with pre-diabetes. IL13 (0.67), IL17 (0.76) and CRP (1.32) remained associated with T2D. IL13 (0.55) was the only marker associated with initiation of insulin therapy in diabetics. Various inflammatory markers are associated with progression from normoglycemia to pre-diabetes (IL13, EN-RAGE, CRP), T2D (IL13, IL17, CRP) or insulin therapy start (IL13). Among them, EN-RAGE is a novel inflammatory marker for pre-diabetes, IL17 for incident T2D and IL13 for pre-diabetes, incident T2D and insulin therapy start. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10654-017-0236-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5380703
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-53807032017-04-17 Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study Brahimaj, Adela Ligthart, Symen Ghanbari, Mohsen Ikram, Mohammad Arfan Hofman, Albert Franco, Oscar H. Kavousi, Maryam Dehghan, Abbas Eur J Epidemiol Diabetes Mellitus The immune response involved in each phase of type 2 diabetes (T2D) development might be different. We aimed to identify novel inflammatory markers that predict progression from normoglycemia to pre-diabetes, incident T2D and insulin therapy. We used plasma levels of 26 inflammatory markers in 971 subjects from the Rotterdam Study. Among them 17 are novel and 9 previously studied. Cox regression models were built to perform survival analysis. Main Outcome Measures: During a follow-up of up to 14.7 years (between April 1, 1997, and Jan 1, 2012) 139 cases of pre-diabetes, 110 cases of T2D and 26 cases of insulin initiation were identified. In age and sex adjusted Cox models, IL13 (HR = 0.78), EN-RAGE (1.30), CFH (1.24), IL18 (1.22) and CRP (1.32) were associated with incident pre-diabetes. IL13 (0.62), IL17 (0.75), EN-RAGE (1.25), complement 3 (1.44), IL18 (1.35), TNFRII (1.27), IL1ra (1.24) and CRP (1.64) were associated with incident T2D. In multivariate models, IL13 (0.77), EN-RAGE (1.23) and CRP (1.26) remained associated with pre-diabetes. IL13 (0.67), IL17 (0.76) and CRP (1.32) remained associated with T2D. IL13 (0.55) was the only marker associated with initiation of insulin therapy in diabetics. Various inflammatory markers are associated with progression from normoglycemia to pre-diabetes (IL13, EN-RAGE, CRP), T2D (IL13, IL17, CRP) or insulin therapy start (IL13). Among them, EN-RAGE is a novel inflammatory marker for pre-diabetes, IL17 for incident T2D and IL13 for pre-diabetes, incident T2D and insulin therapy start. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10654-017-0236-0) contains supplementary material, which is available to authorized users. Springer Netherlands 2017-03-03 2017 /pmc/articles/PMC5380703/ /pubmed/28258520 http://dx.doi.org/10.1007/s10654-017-0236-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Diabetes Mellitus
Brahimaj, Adela
Ligthart, Symen
Ghanbari, Mohsen
Ikram, Mohammad Arfan
Hofman, Albert
Franco, Oscar H.
Kavousi, Maryam
Dehghan, Abbas
Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study
title Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study
title_full Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study
title_fullStr Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study
title_full_unstemmed Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study
title_short Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study
title_sort novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the rotterdam study
topic Diabetes Mellitus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380703/
https://www.ncbi.nlm.nih.gov/pubmed/28258520
http://dx.doi.org/10.1007/s10654-017-0236-0
work_keys_str_mv AT brahimajadela novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy
AT ligthartsymen novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy
AT ghanbarimohsen novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy
AT ikrammohammadarfan novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy
AT hofmanalbert novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy
AT francooscarh novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy
AT kavousimaryam novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy
AT dehghanabbas novelinflammatorymarkersforincidentprediabetesandtype2diabetestherotterdamstudy